Home > Boards > US OTC > Medical - Drugs > Roche Holding Ltd. (RHHBY)

Roche dominates the breast cancer treatment industry with

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Scorpion King Member Profile
Followed By 3
Posts 638
Boards Moderated 0
Alias Born 05/24/13
160x600 placeholder
BioMarin gains on speculation of potential takeover interest (update) Seeking Alpha - 3/1/2021 2:36:43 PM
Roche's Coronavirus Rapid Antigen Test Approved in Germany Dow Jones News - 2/26/2021 1:23:00 PM
Regeneron's antibody cocktail is set for marketing approval in EU Seeking Alpha - 2/26/2021 9:21:08 AM
European Medicines Agency Supports Roche's Covid-19 Antibody Cocktail Dow Jones News - 2/26/2021 8:05:00 AM
Roche Gets Recommendation for Use of Spinal Muscular Atrophy Treatment in Europe Dow Jones News - 2/26/2021 7:13:00 AM
Spark Therapeutics names Cynthia Pussinen chief technical officer Seeking Alpha - 2/25/2021 7:46:00 AM
Chugai in-licenses AT-527 rights from Roche for COVID-19 in Japan Seeking Alpha - 2/19/2021 9:12:38 AM
Piper Sandler initiates Infinity Pharmaceuticals at overweight Seeking Alpha - 2/18/2021 3:39:00 PM
Roche downgraded to neutral at UBS citing heightened Street forecasts Seeking Alpha - 2/17/2021 1:05:51 PM
Roche receives Canadian approval for COVID-19 antigen test Seeking Alpha - 2/17/2021 12:10:13 PM
Roche’s Faricimab dosing interval can be extended up to four months, new data show Seeking Alpha - 2/12/2021 4:52:12 PM
Roche arthritis drug Actemra cuts death risk in hospitalized COVID-19 patients Seeking Alpha - 2/11/2021 10:25:58 AM
Atea discloses new pre-clinical data for experimental COVID-19 antiviral therapy Seeking Alpha - 2/8/2021 5:06:57 PM
Roche 2020 Net Profit Rises But Biosimilars Continue to Pose Headwinds -- Earnings Review Dow Jones News - 2/4/2021 10:08:00 AM
Roche 2020 Net Profit Up Slightly; Proposes Dividend Increase Dow Jones News - 2/4/2021 2:05:00 AM
Roche Gets CE Mark for Latest Covid-19 Nasal Antigen Test Dow Jones News - 2/1/2021 12:19:00 PM
Regeneron: REGEN-COV Is Active Against U.K., South Africa SARS-CoV-2 Variants Dow Jones News - 1/27/2021 8:05:00 AM
Roche's Eye Drug Faricimab Meets Primary Endpoint Dow Jones News - 1/25/2021 1:44:00 AM
Genentech's Esbriet Gets FDA Priority Review in Unclassifiable Interstitial Lung Disease Dow Jones News - 1/21/2021 7:09:00 AM
Correction to Roche Influenza Treatment Article Dow Jones News - 1/11/2021 1:55:00 AM
Roche Influenza Treatment Approved by European Commission Dow Jones News - 1/11/2021 1:43:00 AM
Roche's Genentech Gets FDA Breakthrough Designation for Tiragolumab Combo Dow Jones News - 1/5/2021 7:08:00 AM
Roche's Faricimab Meets Primary Endpoint in Two Phase 3 Studies Dow Jones News - 12/21/2020 1:44:00 AM
Roche Receives U.S. FDA Approval for Ocrelizumab's Two-Hour Infusion Time Dow Jones News - 12/15/2020 2:37:00 AM
Relay Therapeutics Inks RLY-1971 License, Collaboration Deal With Genentech Dow Jones News - 12/14/2020 9:03:00 AM
Scorpion King   Sunday, 06/09/13 09:49:34 AM
Re: None
Post # of 251 
Roche dominates the breast cancer treatment industry with sales of Herceptin that totaled $6 billion in 2012. Roche has also recently garnered FDA approval for Kadcyla, or TDM-1, combining Herceptin with emtansine to earn the nickname “Super Herceptin” as a stronger form of the therapy that has investors excited about the potential sales. The key factor in the case of breast cancer is that Herceptin treats HER-2 (Human Epidermal Growth Factor Receptor 2) positive patients that only account for about 20 percent of the breast cancer population annually. Breast cancer patients that are topoisomerase 2-positive, represent a larger population, but there are no FDA-approved drugs for this group of patients, leaving them little options in treatment. As aforementioned, Adva-27a is directed at topoisomerase 2-positive patients, lending to the premise that the potential sales for the drug could be far greater than Roche’s product.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences